Recent trends and future directions for the medical treatment of ulcerative colitis

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.

Original languageEnglish
Pages (from-to)329-336
Number of pages8
JournalClinical Journal of Gastroenterology
Volume9
Issue number6
DOIs
Publication statusPublished - 2016 Dec 1

Fingerprint

Ulcerative Colitis
Mesalamine
Therapeutics
Tumor Necrosis Factor-alpha
Adrenal Cortex Hormones
Direction compound
Budesonide
Herbal Medicine
Colitis
Physicians

Keywords

  • Anti-adhesion antibody
  • Anti-TNF treatments
  • Calcineurin inhibitors
  • The current treatment guideline for UC
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Recent trends and future directions for the medical treatment of ulcerative colitis. / Naganuma, Makoto; Mizuno, Shinta; Nanki, Kosaku; Sugimoto, Shinya; Kanai, Takanori.

In: Clinical Journal of Gastroenterology, Vol. 9, No. 6, 01.12.2016, p. 329-336.

Research output: Contribution to journalReview article

@article{7ae57c3ec8e242b0bd025a56e3cade1c,
title = "Recent trends and future directions for the medical treatment of ulcerative colitis",
abstract = "Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.",
keywords = "Anti-adhesion antibody, Anti-TNF treatments, Calcineurin inhibitors, The current treatment guideline for UC, Ulcerative colitis",
author = "Makoto Naganuma and Shinta Mizuno and Kosaku Nanki and Shinya Sugimoto and Takanori Kanai",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s12328-016-0686-z",
language = "English",
volume = "9",
pages = "329--336",
journal = "Clinical Journal of Gastroenterology",
issn = "1865-7257",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Recent trends and future directions for the medical treatment of ulcerative colitis

AU - Naganuma, Makoto

AU - Mizuno, Shinta

AU - Nanki, Kosaku

AU - Sugimoto, Shinya

AU - Kanai, Takanori

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.

AB - Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.

KW - Anti-adhesion antibody

KW - Anti-TNF treatments

KW - Calcineurin inhibitors

KW - The current treatment guideline for UC

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85011565770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011565770&partnerID=8YFLogxK

U2 - 10.1007/s12328-016-0686-z

DO - 10.1007/s12328-016-0686-z

M3 - Review article

VL - 9

SP - 329

EP - 336

JO - Clinical Journal of Gastroenterology

JF - Clinical Journal of Gastroenterology

SN - 1865-7257

IS - 6

ER -